Cadrenal Therapeutics (CVKD) closed at $0.98 on November 6, 2026, down 2.0% from the previous close, on volume of 28,409 shares (30-day average 165,648).
Data as of November 6, 2026.
Globe Newswire (Wed, 7-Oct 7:00 AM ET)
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
Globe Newswire (Mon, 21-Sep 4:30 PM ET)
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Globe Newswire (Thu, 3-Sep 8:00 AM ET)
Globe Newswire (Mon, 31-Aug 8:00 AM ET)
Globe Newswire (Thu, 13-Aug 4:15 PM ET)
Market Chameleon (Wed, 17-Dec 4:24 AM ET)
Market Chameleon (Thu, 11-Dec 3:34 AM ET)
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
Cadrenal Therapeutics trades on the NASDAQ stock market under the symbol CVKD.
As of November 6, 2026, CVKD stock price declined to $0.98 with 28,409 million shares trading.
CVKD has a beta of 2.15, meaning it tends to be more sensitive to market movements. CVKD has a correlation of 0.08 to the broad based SPY ETF.
CVKD has a market cap of $3.50 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, CVKD traded as high as $32.55 and as low as $.82.
The top ETF exchange traded funds that CVKD belongs to (by Net Assets): VXF, DFSU.
CVKD has underperformed the market in the last year with a return of -92.0%, while the SPY ETF gained +10.8%. In the last 3 month period, CVKD fell short of the market, returning -47.6%, while SPY returned -4.1%. However, in the most recent 2 weeks CVKD has outperformed the stock market by returning +2.1%, while SPY returned -3.2%.
CVKD support price is $.92 and resistance is $1.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CVKD shares will trade within this expected range on the day.
